心房颤动市场规模、份额及成长分析（按治疗类型、最终用途和地区）－2025-2032 年产业预测

Atrial Fibrillation Market Size, Share, and Growth Analysis, By Treatment type (Pharmacological Treatment, Non-Pharmacological Treatment), By End-Use (Hospitals, Specialty Clinics), By Region - Industry Forecast 2025-2032

出版日期: 2025年03月12日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2023 年心房颤动市场规模价值为 233.1 亿美元，预计将从 2024 年的 258.5 亿美元增长到 2032 年的 591.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 10.9%。

由于心房颤动盛行率不断上升（尤其是在老龄化社会）以及心导管电气烧灼术等治疗技术的进步，心房颤动市场正在经历显着增长。目前，美国约有2%的65岁以下人群和约9%的65岁以上人群被诊断患有心房颤动，预计到2050年，美国心房颤动患者人数将迅速增加到600万至1600万，到2060年，欧洲心房颤动患者人数将增加到900万至1400万。然而，市场挑战依然存在，包括专家短缺和治疗成本上升。雷射和射频应用等新治疗方法的整合既是挑战也是机会。此外，药物和设备的协同效应有望改善治疗效果，进而进一步扩大市场。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业市场定位（2024年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2024年）
主要企业简介
- 公司详情
- 产品系列分析
- 公司分部份额分析
- 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

Johnson & Johnson（USA）
Abbott Laboratories（USA）
Medtronic plc（Ireland）
Boston Scientific Corporation（USA）
AtriCure Inc.（USA）
MicroPort Scientific Corporation（China）
Koninklijke Philips NV（Netherlands）
Biotronik SE & Co. KG（Germany）
Siemens AG（Germany）
Boehringer Ingelheim GmbH（Germany）
Sanofi-Aventis（France）
Bristol-Myers Squibb Company（USA）
CardioFocus Inc.（USA）
Biosense Webster Inc.（USA）
Endoscopic Technologies Inc.（USA）
St. Jude Medical（USA）
AliveCor, Inc.（USA）
Milestone Pharmaceuticals Inc.（Canada）

结论和建议

简介目录

Product Code: SQMIG35E2044

Atrial Fibrillation Market size was valued at USD 23.31 billion in 2023 and is poised to grow from USD 25.85 billion in 2024 to USD 59.15 billion by 2032, growing at a CAGR of 10.9% during the forecast period (2025-2032).

The atrial fibrillation (AFib) market is witnessing significant growth, driven by rising incidence rates, particularly among the aging population, and advancements in treatment technologies like catheter ablation. Currently, about 2% of individuals under 65 and nearly 9% of those over 65 in the U.S. are diagnosed with AFib, with projections indicating that cases could soar to between 6-16 million by 2050 in the U.S. and from 9 million to 14 million in Europe by 2060. However, market challenges, including a shortage of specialists and the high costs of treatment, persist. The integration of novel therapies, such as laser and radiofrequency applications, poses both a challenge and opportunity, as do synergies between medications and devices that could enhance management outcomes and stimulate further market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Atrial Fibrillation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Atrial Fibrillation Market Segments Analysis

Global Atrial Fibrillation Market is segmented by Treatment type, End-Use and region. Based on Treatment type, the market is segmented into Pharmacological Treatment and Non-Pharmacological Treatment. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Atrial Fibrillation Market

The atrial fibrillation market is primarily driven by the increasing aging population, which is particularly susceptible to this condition. According to the World Health Organization (WHO), by 2030, roughly one in six people worldwide will be aged 60 or older, indicating a significant demographic shift. The number of individuals in this age group is projected to grow from 1 billion in 2020 to 1.4 billion in 2030, and by 2050, it is expected to reach 2.1 billion. Moreover, there will be a substantial rise in the population aged 80 and above, with estimates suggesting a threefold increase to 426 million by 2050. This demographic trend highlights the urgent need for effective treatments and management strategies for atrial fibrillation as the population ages.

Restraints in the Atrial Fibrillation Market

The substantial expenses associated with treating atrial fibrillation represent a significant obstacle to the advancement of the atrial fibrillation market. According to research from Science Direction, the average hospitalization cost per patient is approximately USD 3,530 (with a 95% confidence interval of $3,328 to $3,732), while outpatient facility visits average around USD 3,878 (with a 95% confidence interval of $3,769 to $3,987). Additionally, emergency room visits incur an average charge of $394 (with a 95% confidence interval of $358 to $430). These high treatment costs are likely to impede the growth of the atrial fibrillation market significantly.

Market Trends of the Atrial Fibrillation Market

The atrial fibrillation (AFib) market is witnessing significant growth driven by the rising prevalence of the condition, which currently affects approximately 37.57 million individuals worldwide. The National Institutes of Health reports a 33% increase in incidence over the past two decades, highlighting a concerning trend, particularly in countries with middle socio-demographic indices. Modern lifestyle factors, including obesity, hypertension, and diabetes, are exacerbating the situation, further contributing to the market's expansion. As healthcare systems adapt to manage this growing demand, the AFib market is poised for innovation, with an increase in treatment options, diagnostic tools, and patient management solutions emerging as key trends.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement

Global Atrial Fibrillation Market Size by Treatment type & CAGR (2025-2032)

Market Overview
Pharmacological Treatment
- Anti-arrhythmic Drugs
- Anticoagulant Drugs
Non-Pharmacological Treatment
- Catheter Ablation
- Radiofrequency
- HIFU
- Cryoablation
- Microwave
- Laser
- Maze Surgery
- Electric Cardioversion

Global Atrial Fibrillation Market Size by End-Use & CAGR (2025-2032)

Market Overview
Hospitals
Specialty Clinics
Others

Global Atrial Fibrillation Market Size & CAGR (2025-2032)

North America (Treatment type, End-Use)
- US
- Canada
Europe (Treatment type, End-Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment type, End-Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment type, End-Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment type, End-Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AtriCure Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MicroPort Scientific Corporation (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koninklijke Philips N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotronik SE & Co. KG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi-Aventis (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CardioFocus Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biosense Webster Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Endoscopic Technologies Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
St. Jude Medical (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AliveCor, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Milestone Pharmaceuticals Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments